Table: Anges - 9-MTH group results
Oct 29 (Reuters)-
Anges, Inc.
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
9 months ended 9 months ended Year to
Sep 30, 2018 Sep 30, 2017 Dec 31, 2018
LATEST YEAR-AGO LATEST
RESULTS RESULTS FORECAST
Sales 276 mln 255 mln 600 mln
(+8.2 pct) (-0.4 pct) (+64.3 pct)
Operating loss 2.24 loss 2.74 loss 3.10
Recurring loss 2.26 loss 2.76 loss 3.10
Net loss 2.20 loss 3.36 loss 3.10
EPS loss 26.12 yen loss 44.64 yen loss 36.06 yen
Ann Div NIL NIL
-Q2 div NIL NIL
-Q4 div NIL NIL
NOTE - Anges, Inc..
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4563.T
Recent news on AnGes
See all newsTable: Anges -Q1 group results
Brief: Vasomune Therapeutics, Inc., And Anges, Inc., Announce Us FDA Clearance Of Investigational New Drug (Ind) Application For Pegevongitide (Av-001) Treatment In Resuscitation Of Severely Burned Patients
Table: Anges -2025 parent results
Table: Anges -2025 group results
Brief: Anges & Vasomune Therapeutics Enter Agreement For AV-001